• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Bio-Matrix Scientific Group, Inc. Highlighted in LifeSciencesWorld.com Special Report; Stem Cell Market Projected to Exceed $8 Billion Worldwide by 2016

Posted on: Tuesday, 3 March 2009, 09:00 CST

SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN) (http://www.BMSN.us), an emerging research and development biotechnology company focused on the full spectrum of adult stem cells at its commercial cryogenic stem cell bank and processing facility located here, is highlighted in a News/Special Report about trends in adult stem cells published this week as an exclusive to online LifeSciencesWorld (http://www.LifeSciencesWorld.com) that projects the overall market to exceed $8 billion worldwide by 2016 and the umbilical cord blood market estimated to reach approximately $1 billion by 2010.

The Special Report, "Discoveries of Stem Cell Derived from Menstrual Blood Significant Step Forward to Transplantation as Industry Focuses on Other Principle Sources in Therapeutics" by New York City-based author and writer Sally Robbins, provides an overview of the sector, including how a new type of stem cell derived from menstrual blood and other discoveries are providing significant steps forward in providing an ethical, easily accessible, and potentially highly useful adult stem cell for treatment of numerous degenerative conditions.

David Koos, Chairman and CEO of BMSN, is quoted in the report stating: "The recent discovery of the novel stem cell population in menstrual blood and related findings are scientific breakthroughs that are opening the doors to a new dimension in private stem cell/family banking, which has been primarily focused on umbilical cord blood." The report also reviews how BMSN is poised for growth by focusing on the full scope of adult stem cells: cord blood, peripheral blood, bone marrow, menstrual blood and adipose (fat) tissue by forging strategic partnerships in bringing together the necessary resources to offer key technologies in stem cell cryogenics, therapies and bio-medical devices for improving the quality of life.

The article also chronicles in-depth the new developments in umbilical cord blood technologies and the ways in which private stem cell banks in the industry are consolidating.

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company that commercializes medical devices and monitoring systems for the growing worldwide stem cell research market. Its new facility houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

SOURCE Bio-Matrix Scientific Group, Inc.

Source: PR Newswire

More News in this Category